Literature DB >> 710679

Effects of prostaglandin E1 and prostaglandin F2alpha on insulin and glucagon plasma levels during the intravenous glucose tolerance test in man.

D Giugliano, R Torella, L Improta, F D'Onofrio.   

Abstract

The influence of prostaglandin E1 and prostaglandin F2alpha on circulating concentrations of insulin and glucagon during the intravenous glucose tolerance test has been studied in normal man. Insulin responses to glucose during PGE1 infusion (0.2 microgram/Kg/min) were significantly lower than in control infusions (p less than 0.001 at 2, 5, 10 and 15 min). Moreover, PGE1 caused a clear elevation of basal glucagon (p less than 0.02). PGF2alpha, at the two doses used (0.2 and 0.5 microgram/Kg/min), had no effect on basal glucose, insulin and glucagon levels, nor upon glucose-induced insulin secretion. Neither prostaglandin affected the glucose-induced inhibition of pancreatic alpha-cells. There is thus some evidence that PGs of E series may play some role in modulating the secretion of human pancreatic beta-cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 710679

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  4 in total

Review 1.  Opioid peptides and glucose metabolism.

Authors:  A Lala; P Bouloux; G Tamburrano; E Gale
Journal:  J Endocrinol Invest       Date:  1987-02       Impact factor: 4.256

2.  Effect of furosemide on insulin and glucagon responses to arginine in normal subjects.

Authors:  D Giugliano; R Torella; S Sgambato; F D'Onofrio
Journal:  Diabetologia       Date:  1980-04       Impact factor: 10.122

3.  Mechanism of hyperglycemia induced by extensive wounds and generalized surgical infection.

Authors:  S A Morenkova
Journal:  Acta Diabetol Lat       Date:  1987 Apr-Jun

4.  The effect of acetylsalicylic acid on insulin response to glucose and arginine in normal man.

Authors:  D Giugliano; R Torella; N Siniscalchi; L Improta; F D'Onofrio
Journal:  Diabetologia       Date:  1978-06       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.